川崎病急性期治療:歴史的変遷から最新エビデンス,今後の展望
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Kawasaki disease (KD) is an acute systemic vasculitis and a major cause of acquired heart disease in children. The prevention of coronary artery aneurysms has been the central goal of acute-phase treatment, and therapeutic strategies have evolved substantially over the past decades. Early management relied on aspirin monotherapy, which provided symptomatic improvement but failed to adequately prevent coronary complications. The introduction of intravenous immunoglobulin (IVIG) in the 1980s represented a major paradigm shift, and high-dose IVIG combined with aspirin subsequently became the standard of care. Further advances in risk stratification enabled the identification of patients at high risk for IVIG resistance, leading to the adoption of intensified initial therapy, including corticosteroid combination regimens. More recently, additional immunomodulatory agents have expanded therapeutic options for refractory cases, allowing for a more individualized treatment approach. This review summarizes the historical evolution of acute-phase KD management, outlines current evidence-based treatment strategies, and discusses emerging concepts that may shape future practice. Emphasis is placed on risk-based treatment selection and early therapeutic decision-making as key components for improving coronary outcome.
Fields of Study & Subjects
Kawasaki Disease and Coronary Complications
Autoimmune and Inflammatory Disorders Research
Vasculitis and related conditions
Publication details
- Journal / source
- Institutional Repositories DataBase (IRDB)
- Volume
- 6
- Issue
- 1
- Pages
- 3–11
- Publication date
- 15 March 2026
- Language
- JA